(Q34207379)

31 July 2017

title

Is there something other than imatinib mesilate in therapeutic options for GIST? (English)

1 reference

31 July 2017

1 reference

2

Giuseppe Colucci

1 reference

31 July 2017

Francesco Giuliani

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

23 March 2012

1 reference

Expert Opinion on Therapeutic Targets

31 July 2017

published in

1 reference

31 July 2017

volume

16 Suppl 2

1 reference

31 July 2017

page(s)

S35-43

1 reference

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Biology of gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Gastrointestinal stromal tumor: a bridge between bench and bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.657627

10.1517/14728222.2012.657627

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference